First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bowel Disease. MAP 315, is a novel live biotherapeutic ...

Iterative Scopes DDW Presentation Shows Accuracy of Automated Endoscopic Disease Scoring Model, With Potential to Accelerate IBD Clinical Trials. ... a common type of inflammatory bowel disease ...

MORRIS PLAINS, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for ...

A video presentation of ... GMP compliant MAP 315 at large-scale in their state-of-the-art facilities in Europe to supply material for the MAP 315 clinical trial. Inflammatory Bowel Disease ...